Yes, Mounjaro can improve insulin sensitivity, and there is clinical evidence to support this. In a post hoc analysis of SURPASS 2, HOMA2 IR fell by 15.5% to 24.0% after 40 weeks of tirzepatide, compared with 5.1% with semaglutide 1mg. However, insulin resistance itself is not a licensed indication for Mounjaro in the UK. That distinction is important when considering whether treatment is suitable.
Whether you searched insulin resistance and Mounjaro, insulin resistance Mounjaro or Mounjaro insulin resistance UK, the question is usually the same: can Mounjaro help with insulin resistance, and how quickly might changes happen? This guide explains what the evidence shows and when different changes may be seen. It also covers prediabetes, PCOS, metformin, plateaus and what may happen after stopping treatment.
Key things to know
- Mounjaro is licensed in the UK for type 2 diabetes and for weight management. Insulin resistance itself is not a licensed indication.
- Blood glucose can respond within days, but HbA1c reflects average blood glucose over roughly the previous two to three months, so it takes longer to show a clear change.
- Tirzepatide may improve insulin sensitivity through weight loss and through effects that are not fully explained by weight loss alone.
- In adults with prediabetes and obesity or overweight, three years of treatment was associated with a 94% lower risk of progression to type 2 diabetes compared with placebo.
- Some of the improvements seen during treatment may reduce after treatment stops.
- Insulin resistance is assessed using blood tests and other clinical measures. It cannot be reliably judged from symptoms or how you feel from week to week.
Does Mounjaro help with insulin resistance
If you are asking does Mounjaro work for insulin resistance, will Mounjaro help with insulin resistance or is Mounjaro good for insulin resistance, the short answer is that tirzepatide has been shown to improve insulin sensitivity and glucose control.
Mounjaro is licensed in the UK for type 2 diabetes and, separately, for weight management in adults who meet the relevant BMI criteria. It is not licensed specifically to treat insulin resistance, prediabetes or PCOS as conditions on their own.
So, if you are asking whether Mounjaro is used for insulin resistance, the answer depends on why treatment is being considered. If you have type 2 diabetes or meet the criteria for weight management, improvements in insulin sensitivity may occur as part of treatment. If you do not meet those criteria, prescribing Mounjaro specifically for insulin resistance would be outside its licensed indications and requires an individual clinical decision by a prescriber.
You can review current Mounjaro injection pricing and strengths beforehand, but whether treatment is suitable is decided by the prescriber, not the checkout.
How does Mounjaro improve insulin sensitivity
Mounjaro may improve insulin sensitivity through several effects in the body. Tirzepatide acts on two receptors, GIP and GLP 1, which is different from medicines that act on the GLP 1 receptor alone.
One important factor is weight loss. Excess body fat, particularly around the abdomen and liver, can contribute to insulin resistance. Losing weight may therefore improve how the body responds to insulin. This means some of the improvement in insulin sensitivity seen with tirzepatide is linked to weight loss.
There also appears to be an effect that cannot be explained by weight loss alone. Earlier studies found that the improvement in insulin sensitivity was only partly explained by weight loss, suggesting that tirzepatide may also have direct metabolic effects.
Hyperinsulinaemic euglycaemic clamp studies are considered one of the more detailed ways of measuring insulin sensitivity. These studies found a significant increase in insulin sensitivity after 26 weeks of tirzepatide 15mg.
Alongside these effects, tirzepatide injection UK treatment can slow gastric emptying and reduce glucagon release. These effects can influence how quickly glucose enters the bloodstream after meals and how much glucose the liver releases.
What the evidence actually shows
This is where the numbers are useful, because they show what has actually been measured in clinical studies.
| Measure | What the trials found |
|---|---|
| HOMA2 IR (insulin resistance index) | Fell by 15.5% to 24.0% at 40 weeks with tirzepatide 5mg, 10mg and 15mg, compared with 5.1% with semaglutide 1mg (SURPASS 2 post hoc analysis, 1,879 adults with type 2 diabetes) |
| Beta cell function (HOMA2 B) | Increased by 96.9% to 120.4% with tirzepatide, compared with 84.0% with semaglutide 1mg |
| Insulin sensitivity by clamp study | A significant increase was seen after 26 weeks with tirzepatide 15mg |
| HbA1c in type 2 diabetes | Fell to 6.08% (43 mmol/mol) with 5mg monotherapy at 40 weeks, with 34% reaching below 5.7% (39 mmol/mol) in SURPASS 1 |
| HbA1c without diabetes | Fell by around 0.51% with 15mg at 72 weeks in SURMOUNT 1. The change was smaller because baseline levels were already close to normal |
| Progression to type 2 diabetes | The risk was 94% lower over 176 weeks in adults with prediabetes, with 0.41% developing diabetes compared with 6.9% with placebo |
Two things are important to keep in mind. HbA1c tends to change more when someone starts with raised blood glucose, so comparing your result with a diabetes trial may be misleading if your glucose levels were already close to normal.
Fasting insulin may also fall alongside HOMA2 IR. This can indicate that the body is managing glucose with less insulin, although these results need to be interpreted alongside other health measures.
Mounjaro insulin resistance week by week
There is no official Mounjaro metabolic changes timeline, Mounjaro glucose levels timeline or week by week schedule for insulin sensitivity. So, be cautious of any page that presents an exact weekly pattern as something everyone should experience.
The table below gives a general idea of what may happen based on how tirzepatide works and what has been seen in clinical studies. It is not a prediction of what will happen to you.
| Period | What may be happening |
|---|---|
| Week 1 | Glucose responses after meals may begin to change. Appetite changes may also occur early in treatment. |
| Weeks 2 to 4 | Tirzepatide levels build towards a steady state because its half life is around five days. Fasting glucose may begin to change. |
| Weeks 5 to 12 | Weight changes may become more noticeable, and dose increases may take place according to the prescribed schedule and individual tolerance. Insulin sensitivity may also continue to improve. |
| Around 12 weeks | HbA1c can provide a more useful picture of average glucose during treatment. |
| 3 to 6 months | Changes in fasting insulin and HOMA IR may be detectable if these tests are taken. |
| 6 months onwards | Changes may continue with ongoing treatment, depending on factors such as dose, weight change, diet, activity and individual response. |
Mounjaro blood sugar first week
Glucose levels can start to respond soon after beginning Mounjaro. Tirzepatide can slow gastric emptying and reduce glucagon release, which can affect blood glucose levels after meals.
However, an early change in blood glucose does not necessarily mean that insulin resistance has already improved to the same extent. Insulin sensitivity is influenced by several factors, including weight, activity, diet and how the body responds to insulin over time.
If you use insulin or certain diabetes medicines, such as sulfonylureas, Mounjaro may increase the risk of hypoglycaemia when used alongside them. Your healthcare professional may need to review your diabetes medicines when starting or changing treatment. Do not change your doses without medical advice.
Mounjaro week 4 what to expect
By around week four, tirzepatide has been given at the starting dose for several weeks, and your prescriber may review how you are responding to treatment. The dose may then be increased according to the licensed dosing schedule and how well you tolerate it.
Some people notice changes in appetite or how full they feel during the first few weeks. Weight loss may also begin, although the amount varies considerably between people.
Blood glucose may also change during this period, particularly in people using Mounjaro for type 2 diabetes. However, week four is still relatively early, so it may not be possible to judge the full effect of treatment at this point.
This is also a useful time to discuss side effects with your prescriber. Nausea, diarrhoea, vomiting and other gastrointestinal side effects can occur with Mounjaro, particularly when treatment starts or the dose is increased.
Mounjaro 12 weeks results and Mounjaro HbA1c week by week
HbA1c cannot be meaningfully tracked from one week to the next. It reflects average blood glucose over roughly the previous two to three months, although more recent weeks can have a greater influence on the result.
This is why an HbA1c test at week four may still reflect a large part of the period before you started Mounjaro.
Around 12 weeks can therefore be a more useful point for reviewing HbA1c because the result reflects a longer period of treatment. Your healthcare professional may also look at fasting glucose, weight and other relevant measurements.
Fasting glucose can change much sooner than HbA1c, so it may be useful for monitoring short term changes where clinically appropriate.
Signs Mounjaro is working
Some changes can be noticeable, such as reduced appetite, feeling full sooner or changes in weight. If you have type 2 diabetes, your blood glucose readings may also change.
However, insulin sensitivity itself does not have a reliable set of symptoms. You cannot tell from how you feel alone whether your insulin resistance has improved.
This is why blood tests and other clinical measurements are more useful when assessing changes in insulin sensitivity. If you are monitoring your treatment, your healthcare professional can advise which measurements are appropriate for you.
Can Mounjaro reverse insulin resistance
Mounjaro may improve insulin resistance, but it is more accurate to describe this as improvement rather than a guaranteed reversal or cure.
Insulin resistance can change over time. Weight, physical activity, sleep, diet and other health factors can all influence how the body responds to insulin. Clinical studies of tirzepatide have also shown improvements in measures such as HOMA2 IR and insulin sensitivity.
Whether insulin resistance returns to a normal range depends on the individual and the underlying cause. Someone with less severe insulin resistance who loses weight may see their glucose handling move closer to the normal range. Someone with long standing type 2 diabetes may have additional changes in insulin production and beta cell function that make the situation more complex.
The important point is that improvements are not necessarily permanent. If treatment is stopped or other factors affecting insulin resistance change, some of the metabolic benefits may reduce over time.
Mounjaro for insulin resistance without diabetes, and Mounjaro prediabetes UK guidance
This is one of the most common questions, and there is useful evidence to consider. SURMOUNT 1 followed 1,032 adults with prediabetes and obesity or overweight for 176 weeks. In the study, progression to type 2 diabetes was 94% lower with tirzepatide than with placebo. In absolute terms, 0.41% of people taking tirzepatide developed diabetes compared with 6.9% taking placebo. This meant that nearly 99% of participants in the tirzepatide group had not developed diabetes at three years. Average weight reduction reached 22.9% with 15mg.
These results are encouraging, but they do not mean that Mounjaro prevents diabetes for everyone who takes it. The study included specific groups of adults and the results cannot be used to predict exactly what will happen to an individual.
In the UK, prediabetes is usually defined by an HbA1c of 42 to 47 mmol/mol, while 48 mmol/mol or above is within the diabetes range. Having prediabetes alone does not automatically make you eligible for a private prescription for Mounjaro. Eligibility depends on the licensed indication being considered, such as the weight management criteria, or on a diagnosis of type 2 diabetes.
Raised HbA1c can still be an important part of your overall health assessment. If you have prediabetes, it is also worth discussing lifestyle support and the NHS Diabetes Prevention Programme with your GP. You can also compare weight loss treatment options before deciding which approach may be suitable for you.
Mounjaro, insulin resistance, PCOS and fertility
Insulin resistance is common in people with PCOS, so it is understandable that there is interest in whether Mounjaro could help. However, PCOS is not a licensed indication for Mounjaro.
If a woman with PCOS also meets the relevant weight management criteria, a prescriber may consider tirzepatide for weight management. Weight loss may also help some people with PCOS with menstrual regularity and ovulation, although individual results vary. Mounjaro should not be viewed as a treatment for PCOS itself and does not replace appropriate care for the condition.
There is also an important point about contraception. MHRA advice from June 2025 states that women using oral contraception with tirzepatide should use a barrier method or switch to a non oral contraceptive method for four weeks after starting tirzepatide and for four weeks after each dose increase. This is because tirzepatide can delay gastric emptying, which may affect the absorption of oral contraceptives.
This is particularly worth discussing if you have PCOS and are trying to avoid pregnancy. Changes in weight and menstrual patterns can also affect fertility, so speak with your prescriber if pregnancy is possible or planned.
Insulin resistance symptoms in females
The most important thing to know is that insulin resistance often causes no obvious symptoms. This is why it is usually assessed using blood tests and other health measurements rather than symptoms alone.
Some people may develop dark, velvety areas of skin around the neck, armpits or groin. This is called acanthosis nigricans. Skin tags and weight gain around the middle can also occur, although neither confirms insulin resistance.
In women, irregular or missed periods, excess hair growth, acne and difficulty becoming pregnant can occur with PCOS. PCOS and insulin resistance often occur together, but these symptoms do not prove that you have insulin resistance.
Feeling tired after meals, increased thirst or needing to urinate more often can have many different causes. They should not be used to diagnose insulin resistance on their own. If you are concerned, speak with your GP about whether blood tests or other checks are appropriate.
Insulin resistance means that the body's cells do not respond to insulin as effectively as they should. The pancreas may then produce more insulin to help keep blood glucose within the normal range. Over time, insulin resistance can be linked with a higher risk of type 2 diabetes and other metabolic health problems.
Managing insulin resistance usually involves several factors. These can include a balanced diet, regular physical activity, maintaining a healthy weight where appropriate, good sleep and treatment of any underlying conditions. Medicines may also be used when clinically appropriate.
Mounjaro is not licensed specifically to treat insulin resistance. However, tirzepatide can improve blood glucose control and is used for type 2 diabetes and weight management in people who meet the relevant criteria. Clinical studies have also found improvements in measures of insulin sensitivity during treatment.
If you have symptoms that concern you, or you are worried about your blood glucose or metabolic health, speak with your healthcare professional. They can help decide whether you need testing and which treatment options may be appropriate.
Mounjaro vs metformin for insulin resistance
Mounjaro vs metformin insulin resistance comparisons are common, but the two medicines are not simply alternatives to each other.
| Point of comparison | Metformin | Mounjaro |
|---|---|---|
| UK licence | Type 2 diabetes | Type 2 diabetes and weight management |
| Licensed for insulin resistance | No | No |
| Form | Tablets | Weekly injection |
| Typical cost | Pennies per tablet on the Drug Tariff | £174.99 to £323.99 per pen |
| Effect on weight | Usually modest | Weight loss can be substantial in clinical trials |
Metformin is commonly used as a treatment for type 2 diabetes in the UK and may also be prescribed off label for PCOS. It can improve insulin sensitivity, partly by reducing the amount of glucose produced by the liver. It is also an established and relatively inexpensive medicine.
If you are considering treatment for weight or metabolic health, it can be useful to compare weight loss injections with other treatment options rather than assuming one medicine is automatically better.
Tirzepatide has produced greater average weight loss than metformin in the settings where it has been studied, but the medicines have different licensed uses and work in different ways. In SURPASS 2, HOMA2 IR improvements were seen in people who were already taking metformin. This shows that the two medicines are not necessarily alternatives, and some people may be prescribed both.
Neither medicine is licensed specifically for insulin resistance. The right treatment depends on your diagnosis, health history, other medicines and individual circumstances.
Mounjaro insulin resistance, weight loss plateau and what it means
A weight loss plateau can feel frustrating, but it does not necessarily mean that your treatment has stopped working.
As body weight decreases, the body generally needs fewer calories to maintain that lower weight. This can make further weight loss slower over time. Weight can also naturally move up and down from week to week because of changes in fluid, food intake and other factors.
A plateau in weight does not automatically mean that every other health measure has stopped changing. Blood glucose, blood pressure and other metabolic measurements may change independently of the number on the scales.
If your weight has stayed stable for several weeks or you are concerned that your treatment is no longer suitable, speak with your prescriber. They can look at your weight, blood glucose, dose, side effects and overall health before deciding whether anything needs to change.
Does insulin resistance return after stopping Mounjaro
Some of the improvements seen during Mounjaro treatment may reduce after stopping, particularly if weight is regained. The SURMOUNT 1 data provide useful evidence of this.
During the 17 week off treatment period following the 176 week treatment phase, participants who stopped tirzepatide regained some weight and the difference in diabetes progression between the groups became smaller. The reported risk reduction changed from 94% during treatment to 88% after the off treatment period.
Tirzepatide has a half life of around five days, so its levels gradually fall after the final injection and it takes several weeks for most of the medicine to leave the body.
Changes after stopping are not simply about the medicine leaving your system. Appetite, body weight, physical activity, diet, sleep and other factors can all affect insulin sensitivity. If weight is regained, insulin resistance may also increase again.
This does not mean that stopping treatment is always the wrong decision. If you are thinking about stopping Mounjaro, discuss it with your prescriber first. They can help you understand what may happen and whether you need a plan for maintaining your weight and metabolic health.
Which tests actually measure this
If you want to understand insulin resistance rather than rely on symptoms, several measurements may be considered.
- Fasting glucose and HbA1c. These are widely used blood tests. HbA1c gives an indication of average blood glucose over the previous two to three months.
- Fasting insulin. This can provide information about how much insulin is circulating in the blood, although it is not routinely measured for everyone on the NHS.
- HOMA IR. This is calculated using fasting glucose and fasting insulin. HOMA IR Mounjaro figures appear in clinical research, but there is no single HOMA IR result that can diagnose insulin resistance in every person.
- Waist measurement and triglycerides. These can provide additional information about metabolic health but cannot diagnose insulin resistance on their own.
Routine fasting insulin or HOMA IR testing is not normally required for everyone taking tirzepatide. If you want these tests, discuss them with your GP or prescriber to see whether they are appropriate for your situation.
What treatment costs
Each Mounjaro KwikPen contains four weekly doses, so someone taking treatment continuously for a full year would use 13 pens rather than 12.
| Strength | Standard price | Cost per weekly dose |
|---|---|---|
| 2.5mg | £174.99 | £43.75 |
| 5mg | £204.99 | £51.25 |
| 7.5mg | £254.99 | £63.75 |
| 10mg | £274.99 | £68.75 |
| 12.5mg | £304.99 | £76.25 |
| 15mg | £323.99 | £81.00 |
These are standard UK prices at the time of writing. Live pricing on the product page takes precedence. Pen needles and a sharps bin are purchased separately.
You can review our weight management programme pages to compare available options. All prescription treatment is subject to clinical assessment and approval.
Medical Disclaimer
This page provides general information about Mounjaro and insulin resistance. It is not medical advice, a diagnosis or a substitute for an assessment by a qualified healthcare professional. It cannot tell you whether you have insulin resistance or whether Mounjaro is suitable for you.
Mounjaro is licensed in the UK for type 2 diabetes and for weight management. It is not licensed specifically for insulin resistance, prediabetes or polycystic ovary syndrome. The information on this page should not be taken as a recommendation to use Mounjaro for these conditions. Suitability depends on an individual clinical assessment, and your prescriber will decide whether treatment is appropriate.
The timelines and trial figures discussed on this page are based on published research. They describe results seen in particular study groups and cannot predict exactly what will happen to an individual. Everyone responds differently to treatment.
Never start, stop or change the dose of any medicine based only on information you have read online. This includes insulin, sulfonylureas, metformin and Mounjaro. If you use insulin or a sulfonylurea, taking tirzepatide alongside it can increase the risk of low blood sugar. Your prescriber may need to review your medicines and doses.
If you experience a suspected side effect, you can report it through the MHRA Yellow Card scheme. Seek urgent medical advice if you develop severe or persistent abdominal pain, signs of a serious allergic reaction or symptoms that prevent you from keeping fluids down.
Mounjaro contains tirzepatide, which works on two hormone receptors called GIP and GLP 1. These effects can influence appetite, food intake, gastric emptying and blood glucose regulation. Clinical studies have also found improvements in weight and measures of insulin sensitivity in people taking tirzepatide.
Mounjaro is a prescription only medicine and should be used under appropriate medical supervision. It is not suitable for everyone, and potential benefits and risks should be discussed with a qualified prescriber before treatment begins.